UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of ~~the~~The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~May 294, ~~2012~~ 2012

MABCURE INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation)

333-141131
(Commission File Number)

20-4907813
(IRS Employer Identification No.)

228 Park Ave S #15740
New York, NY 10003
(Address of principal executive offices and Zip Code)

(~~914~~845) ~~595~~591-~~6342~~3144 (Registrant's ~~telephone~~ telephone number, including area code)

~~760 Parkside Ave #208 Brooklyn, New York 11226~~ ____________________________________________________(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

~~Item~~On ~~5.02(c):~~April ~~Mr.~~18, ~~Dov~~2012, ~~Weinberg~~the ~~has~~Board ~~been~~of ~~appointed~~Directors toof the ~~position~~Registrant approved the appointment of ~~Chief~~Ms. ~~Financial~~Vered ~~Officer~~Caplan ofto ~~the~~its ~~Registrant~~Board of Directors.

MrMs. ~~Weinberg~~Caplan, ~~who~~age is43, 59CEO ~~years~~of ~~old~~Kamedis Ltd., isBIC Inc. and Pbd Ltd. From 2008 to 2012, she served as CEO of Kamedis Ltd., a ~~Certified~~derma-cosmetics ~~Public~~company ~~Accountant~~focused ~~since~~on ~~1979~~utilizing ~~and~~plant ~~holds~~extracts anfor ~~MBA~~dermatology purposes, and from ~~Bar~~2004 ~~Ilan~~to 2007, ~~University~~Ms. ~~(1984)~~Caplan ~~and~~served as CEO of GammaCan International, Inc., a pharmaceutical company focused on the use of immunoglobulins for the treatment of cancer. From 1998 to 2008, Ms. Caplan was an active entrepreneur in the life-science arena. Ms. Caplan earned a B.ASc. in ~~Economics~~mechanical engineering from the Technion, and ~~Accounting~~a M.Sc. in bio-medical engineering from Tel -Aviv University ~~(1997)~~.

~~Mr.~~In ~~Dov~~connection ~~Weinberg~~with ~~has more than 11 years of experience in the medical device area~~Ms. HeCaplan's isappointment ~~an owner and president of Weinberg Dalyo Inc., a U.S corporation, which renders business development and financial services~~ to ~~companies~~ in the ~~life~~Board ~~science industry. Mr. Weinberg has been serving as CFO~~ of ~~QRS systems Inc. Innovate Inc. Orgenesis Inc. and NaNaMEd LLC~~Directors, ~~and was~~ the ~~Chief Financial~~Registrant ~~officer~~entered ofinto ~~Impulse~~an ~~Dynamics~~at-will ~~from~~director’s ~~December~~agreement ~~2000~~with ~~till 2009~~Ms. ~~Prior to~~ ~~that~~Caplan, ~~Mr. Weinberg served for more than 15 years as~~ the ~~CFO~~terms of awhich ~~large~~include ~~industrial multinational public corporation in charge of finance, information systems, and taxation of~~ the ~~company~~following: ~~and its worldwide subsidiaries.~~

MrMs. ~~Weinberg~~Caplan entered into a management services agreement with the Registrant on February 29, 2012. The agreement sets forth standard terms of services, covering matters such as financial services and compensation, as well as customary confidentiality and proprietary information provisions. Pursuant to his management services agreement, the Registrant will ~~pay~~receive ~~Mr. Weinberg a monthly fee of~~ $54,000. Inannually ~~addition,~~for ~~the~~her ~~Registrant~~services ~~will~~as ~~grant Mr~~Director. ~~Weinberg~~ 200,000 stock options entitling Mr. Weinberg to purchase 200,000 shares of the Registrant’s common stock at the fair market value of the stock on the date of grant. The stock options will vest over a 3 year period.
~~Item 5~~Ms.~~02(b):~~ ~~After~~Caplan ~~mutual~~will ~~agreement~~receive ~~between~~an ~~the~~additional ~~registrant~~annual ~~and~~payment ~~Mr.~~of ~~Kalfus~~$8,000 ~~Mr.~~if ~~Kalfus’s~~she serves ~~effective~~as ~~date~~a member of ~~resignation~~a ~~has~~committee ~~been~~of ~~advanced~~the ~~from April 30, 2012 to Feb 29, 2012~~Board.
~~SIGNATURES~~The Registrant undertook to grant Ms. Caplan five year stock options to purchase 120,000 shares of the Registrant’s common stock at an exercise price of $0.05 per share.

~~Pursuant~~There toare ~~the~~no ~~requirements~~family ofrelationships ~~the~~between ~~Securities~~any ~~Exchange Act~~ of ~~1934,~~ ~~the~~our ~~Registrant has duly caused this report to be signed on its behalf by~~Directors ~~the~~or ~~undersigned~~executive ~~hereunto duly authorized~~officers.

~~MABCURE~~SIGNATURES ~~INC. (Registrant) By: /s/ Dr. Amnon Gonenne Dr. Amnon Gonenne President and Chief Executive Officer~~

~~Date:~~Pursuant ~~March~~to 1the requirements of the Securities Exchange Act of 1934, ~~2012~~the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MABCURE INC.
	(Registrant)


	By: /s/ Dr. Amnon Gonenne
	Dr. Amnon Gonenne
	President and Chief Executive Officer

Date: May 4, 2012

Filing Compare · MABCURE INC.